CD8A and neoplasm: More than half of the MCT-SCC/ASCs [14/24 (58%)] showed a high number of tumor-infiltrating CD8-positive T cells (Fig. 5a), and the CD8-high group showed a significantly better prognosis than the CD8-low group (Fig. 5b).